Stephen Isaacs's Colleagues at Aduro Biotech
Joel Burrill
director, business development, project management and strategic alliances
Stephen Isaacs's Contact Details
["(510) 848-4400","1-510-848-4400","510-848-4400"]
Aduro Biotech
Stephen Isaacs's Company Details
Aduro is developing novel therapies that induce highly targeted, potent and sustained immune responses against a variety of cancers. We have three diverse immunotherapy platforms – LADD (live, attenuated, double-deleted Listeria mononcytogenes), CDNs (cyclic dinucleotides) and B-select antibodies (B-select) that we believe are key to our fulfillment of our mission to stay at the forefront of discovery, development and commercialization of immunotherapies, alone or in combination; that make transformative advances in the treatment of challenging diseases. Aduro Biotech Europe (previously BioNovion), a subsidiary of Aduro Biotech Inc. is based in the Pivot Park in Oss, The Netherlands. Aduro Biotech Europe focusses among others on the B-select monoclonal antibodies (B-select) platform. This platform is designed to produce first- and best-in-class agonist and antagonist monoclonal antibodies (mAbs) that will be used to create a deep pipeline of products focused on harnessing the immune system of cancer patients. See for more information: www.aduro.com